| Literature DB >> 35741873 |
Matheus Thomaz Nogueira Silva Lima1, Eric Boulanger2, Frédéric J Tessier2, Jacqueline Aparecida Takahashi3.
Abstract
The world is currently undergoing a demographic change towards an increasing number of elderly citizens. Aging is characterized by a temporal decline in physiological capacity, and oxidative stress is a hallmark of aging and age-related disorders. Such an oxidative state is linked to a decrease in the effective mechanisms of cellular repair, the incidence of post-translational protein glycation, mitochondrial dysfunction, and neurodegeneration, just to name some of the markers contributing to the establishment of age-related reduction-oxidation, or redox, imbalance. Currently, there are no prescribed therapies to control oxidative stress; however, there are strategies to elevate antioxidant defenses and overcome related health challenges based on the adoption of nutritional therapies. It is well known that herbal teas such, as hibiscus, rooibos, and yerba mate, are important sources of antioxidants, able to prevent some oxidation-related stresses. These plants produce several bioactive metabolites, have a pleasant taste, and a long-lasting history as safe foods. This paper reviews the literature on hibiscus, rooibos, and yerba mate teas in the context of nutritional strategies for the attenuation of oxidative stress-related glycoxidation and neurodegeneration, and, here, Alzheimer's Disease is approached as an example. The focus is given to mechanisms of glycation inhibition, as well as neuroprotective in vitro effects, and, in animal studies, to frame interest in these plants as nutraceutical agents related to current health concerns.Entities:
Keywords: glycoxidation; herbal teas; neurodegeneration; oxidative stress; therapeutics
Year: 2022 PMID: 35741873 PMCID: PMC9222775 DOI: 10.3390/foods11121676
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1(A) Schematic representation of early stage of the Maillard Reaction and related oxidative pathways. The oxidative cleavage of Schiff base and Amadori Products results in the formation of reactive dicarbonyls. Dicarbonyls are also by-products of glucose autoxidation and glycolysis. Reactive dicarbonylic intermediaries are further involved in glycoxidation leading to the formation of AGEs [54]. Epalrestat, aminoguanidine, pyridoxamine, and alagebrium have been identified as mitigators of the Maillard Reaction, taking part in different steps. (B) The resulting AGEs in the latest phase of the Maillard reaction, both from endogenous and exogenous sources, have been identified as ligands and potential activators of RAGE. Such interaction leads to downstream activation of oxidative stress and inflammation. From the clinical perspective, a therapeutic strategy to mitigate the activation of RAGE, as well as the progression of Alzheimer’s Disease, has been focused on the development of RAGE inhibitors [55].
Figure 2Schematic representation of some biological mechanisms in the interplay of glycation, neurodegeneration, and the progression of oxidative stress. Mechanisms in brain degeneration are highlighted. Both glycation and cellular degeneration are involved in the activation of local (i.e., brain) and systemic oxidative stress. The accumulation of dysfunctional mitochondria, DNA damage, lipid peroxidation, and/or energetic imbalance induces severe damage to cells. AGEs, as well as Aβ-peptides, have related stress activation on membrane-RAGE, which is a promiscuous receptor interacting with both ligands. CML: carboxymethyl-lysine; MG-H1: Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine.
Reported bioactive natural products in rooibos, hibiscus, and/or yerba mate extracts.
| Experimental | Compound | Chemical Structure | Associated Bioactivity | Effect |
|---|---|---|---|---|
| In vitro | Caffeic acid |
| Anti-glycation | AGE formation |
| Epicatechin |
| Neuroprotective | Parkin expression | |
| Hibiscin |
| Anti-inflammatory | IL-6 expression | |
| Quercetin |
| Attenuation of mitophagy | MitoSox | |
| Quinic acid |
| Photoprotective | UVB irradiation-induced ROS generation | |
| Theobromine |
| Adipogenesis attenuation | Adipogenic differentiation | |
| In vivo | Acteoside |
| Glucose metabolism | Blood glucose |
| Aspalathin |
| Nephroprotective | Creatinine levels | |
| Caffeine |
| Anti-AChE | AChE activity | |
| Chlorogenic acid |
| Neuroprotective | Mitochondrial damage |
SGBS: human Simpson-Golabi-Behmel syndrome (SGBS) preadipocyte cell; SHSY5y: human neuroblastoma cell line; RAW262.7: murine monocyte/macrophage-like cells.
Figure 3Commercial (A) rooibos, (B) hibiscus, and (C) green yerba mate dry herbal teas.
Biomarkers related to oxidative stress, glycoxidation, and neurodegeneration.
| Physiological Target | Biomarker | Pathological Implication | Reference |
|---|---|---|---|
| Neurodegeneration | Aβ-peptides | Aβ cerebral deposition increases with AD progression | [ |
| AChE | Participates in acetylcholine level decline in the genesis of AD | ||
| γ-secretase | γ-secretase participates in Aβ-protein processing | ||
| Glycoxidation | Fluorescence (355/460 nm) | Marker of AGE occurrence (e.g., skin) | [ |
| Oxidative stress | CAT | Takes part in cellular oxidative stress mitigation | [ |
| COX-2 | Inflammation and inflammation mediator | [ | |
| GSH/GSSG | Redox balance indicator | [ | |
| H2O2 | Mitochondrial dysfunction | [ | |
| LDH | Energy metabolism and cell senescence control | [ | |
| Lipid peroxidation | Cellular lipid integrity biomarker | [ | |
| MAO-A | Regulates amine metabolism, especially important for neurophysiology, associated with anxiety or depression studies | [ | |
| MPO | MPO is mostly produced by immune cells, especially neutrophils, being involved with both inflammation and oxidative stress | [ | |
| SOD | Plays a role in oxidative stress and cell injury indication | [ | |
| HIAA | Product of serotonin metabolism pathway used as a biomarker of neurological injury | [ |
In vitro antioxidant and anti-glycation effects of rooibos, hibiscus, yerba mate extracts.
| Assay | Species | Measure | Dose or EC50 | Reference |
| Antioxidant | Lipid peroxidation | Control: 800% | [ | |
| ROS production | Control: 130% | |||
| Malondialdehyde | EC50 22 μg/mL | [ | ||
| Monoamine Oxidase | EC50 44 μg/mL | |||
| ATPase activity | EC50 22 μg/mL | |||
| Anti-glycoxidation | AGE formation inhibition | Control (aminoguanidine): 45% | [ | |
| AGE formation inhibition | Control (Aminoguanidine): IC50 6 μg/mL | [ | ||
| AGE formation inhibition | Control (Fructose): 4000 a.u. | [ | ||
| AGE formation inhibition | Control (green tea): 65 a.u. | [ |
BSA: bovine serum albumin.
In vivo antioxidant and anti-glycation effects of rooibos, hibiscus, yerba mate extracts.
| Target Effect/Organ | Species [Extract] | Concentration | Animal Model | Measure | Effect | Tendency | Reference |
|---|---|---|---|---|---|---|---|
| Antioxidant/Brain | 1 g/100 mL | Immobilization-induced oxidative stress Sprague Dawley rats | CAT | Control (Stress): 2 unit/mg | ↑ | [ | |
| FFA | Control (Stress): 700 µg/mL | ↓ | |||||
| GSH/GSSG | Control (Stress): 7.5 | ↑ | |||||
| HIAA | Control (Stress): 400 mg/g tissue | ↓ | |||||
| Lipid peroxidation | Control (Stress): 50 nmol/g tissue | ↓ | |||||
| SOD | Control (Stress): 1 unit/mg | ↑ | |||||
| 25 mg/kg body weight | STZ induced diabetic Male Sprague-Dawley | CAT | Control (Diabetic): 5 U/mg | ↑ | [ | ||
| SOD | Control (Diabetic): 7 U/mg | ↑ | |||||
| 200 mg/kg body weight | Male Swiss albino mice | MDA | Control (STZ): 3 nmol/g | ↓ | [ | ||
| MPO | Control (STZ): 75 µg/mg tissue | ↓ | |||||
| Cox-2 | Control (STZ): 4 (fold change) | ↓ | |||||
| 500 mg/kg body weight | Cypermethrin oxidative stress male mice ( | AChE | Control (Cypermethrin): 0.5 µmol/min/mg | ↓ | [ | ||
| CAT | Control (Cypermethrin): 0.04 µmol/min/mg | ↓ | |||||
| H2O2 | Control (Cypermethrin): 1.2 µmol/mg | ↓ | |||||
| MDA | Control (Cypermethrin): 2 µmol/mg | ↓ | |||||
| 200 mg/mL | Chronic immobilization stress male Wistar rats | GSH/GSSG | Control: 0.48 | → | [ | ||
| Lipid peroxidation | Control: 2.1 TBA/mg | ↓ | |||||
| 200 mg/mL | Male Wistar rats | GSH/GSSG | Control: 4.7 | ↑ | [ | ||
| Lipid peroxidation | Control: 1.3 MDA eq/mg | ↓ | |||||
| 50 mg/kg BW | PTZ-induced seizure male Wistar rats | CAT | Control (PTZ): 5 mmol/min/mg | ↑ | [ | ||
| SOD | Control (PTZ): 15.50 U/mg | ↑ | |||||
| Sulfhydryl protein | Control (PTZ): 0.09 nmol DTNB/mg | ↑ | |||||
| Anti-glycoxidation | 25 mg/kg BW | STZ induced diabetic Male Sprague-Dawley | Glycated hemoglobin | Control: 13% | ↓ | [ | |
| 200 mg/kg BW | STZ induced diabetic Male Sprague-Dawley | Serum glucose | Diabetic control: 400 mg/dL | ↓ | [ | ||
| AGE levels | Diabetic control: 4.5 mg/mL | ↓ |
STZ: streptozotocin.
In vitro neuroprotective effect of aqueous, ethanolic, and methanolic H. sabdariffa extracts.
| Extract | Measure | Dose or EC50 | Reference |
|---|---|---|---|
| Aqueous | AChE inhibition | Control (galantamine): IC50 7 μg/mL | [ |
| Ethanolic | PC12 cells Inhibition of cell apoptosis | Control (SGD): 65 apoptotic cells | [ |
| Methanolic | AChE inhibition | IC50 46.96 μg/mL | [ |
| BChE inhibition | EC50 40.38 μg/mL |
In vivo neuroprotective effects of rooibos, hibiscus, yerba mate extracts.
| Species | Concentration | Animal Model | Measure | Effect | Tendency | Reference |
|---|---|---|---|---|---|---|
| 100 mg/mL | Zebrafish larvae | Monoamine oxidase | Control (Clorgyline): 100% | ↓ | [ | |
| Cell viability | Control: 100% | ↓ | ||||
| 12.5 µg/mL | Zebrafish larvae | ROS production | Control: 600% (120 min) | ↓ | ||
| 200 mg/kg BW | Male Swiss albino mice | Moris water test | Control (STZ): 20 sExtract: 30 s | ↑ | [ | |
| BACE1 | Control (STZ): 5 (fold change) | ↓ | ||||
| Aβ-42 | Control (STZ): 250 mg/mg tissue | ↓ | ||||
| γ-secretase | Control (STZ): 3.5 (fold change) | ↓ | ||||
| 500 mg/kg BW | Swiss albino mice | AChE activity | Control (Scopolamin): 44 nM/min/g tissue | ↓ | [ | |
| 10.5 mg/L |
| Aluminum induced oxidative stress | Control: 0.6 µM/h/mg | ↓ | [ | |
| 4 mg/mL |
| Aβ-42 | Control: 1 a.u. | ↓ | [ | |
| AChE activity | Control: 100% | ↓ | ||||
| Lifespan | Control: 15 days | ↑ | ||||
| ROS production | Control: 100% | ↓ | ||||
| 500 mg/kg | Male C57Bl/6 mice | Catalepsy | Control (reserpine): 120 s | ↓ | [ | |
| 300 mg/kg BW | Male Swiss mice | Elevated Plus Maze | Control: 17% | ↑ | [ | |
| AChE | Control: 4.5 mmol/min/mg | ↑ | ||||
| Step-down avoidance task | Control: 170 s | ↓ |